October 6th 2024
The investigators undertook a study in which they retrospectively evaluated the presence and amount of small HRF in the eyes of patients with different macular atrophic phenotypes.
September 26th 2024
Boehringer Ingelheim to advance potential new treatment for GA following Phase 1 results
September 10th 2024BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.
Annexon provides update on ARCHER II global registrational program in geographic atrophy
August 5th 2024According to the company, additional data from its Phase 2 ARCHER trial showed both vision protection in standard and low light conditions, and structural protection in regions of the eye key for visual acuity.
ASRS 2024: Results of the LIGHTSITE III study
July 29th 2024Eleonora Lad, MD, PhD, spoke about her presentation, "Multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of geographic atrophy in dry age-related macular degeneration" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden.
ASRS 2024: Fas inhibition with ONL-1204 for GA
July 19th 2024Durga Borkar, MD, MMCi, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss Fas inhibition with ONL-1204 for the treatment of geographic atrophy: First-time results from a phase 1b study, which she is presenting at the ASRS meeting held in Stockholm, Sweden.
ASRS 2024: Results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
July 18th 2024Rishi P. Singh, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA at the American Society of Retina Specialists meeting held in Stockholm, Sweden.
ASRS 2024: Predictive role of outer retinal tubulation in GA lesion growth
July 18th 2024Srinivas Sai Kondapalli, MD, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA.
ASRS 2024: What are attendees looking forward to at the conference
July 17th 2024Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, spoke with attendees, who shared which topics they are most looking forward to discussing at the ASRS meeting held in Stockholm, Sweden.
The value of real-world insights in ophthalmology and geographic atrophy (GA) treatment
April 4th 2024Modern Retina’s interview with Aracelis Torres, PhD, MPH sheds light on how real-world insights empower researchers to see trends and develop new strategies, sometimes even new products, to meet the treatment needs of patients.
New dawn of GA management requires renewed attention to imaging
March 18th 2024It is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).
Intraocular inflammation: A major risk factor resulting from use of anti-complement agents for GA
March 15th 2024The good news for patients is that GA is transitioning from an untreatable disease to a potentially treatable one with development of new therapies to reduce the growth rate, and use of anti-complement therapies have caused the growth rate of GA lesions to decrease.